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Summary In a retrospective analysis encompassing a 14 year period (1978-92), 22 patients (age range 19-71,
median 30 years) were identified as having mediastinal large-cell lymphoma with sclerosis on the basis of
clinical and pathological features. At presentation, 15/22 had 'bulky' disease and 11/22 had evidence of
superior vena caval obstruction. Thirteen patients had stage 11 disease (6,11; 7,IIE), nine presented with stage
IV disease. Complete remission (CR) was achieved in only 4/22 patients with the initial adriamycin-containing
regimen. 'Good partial remission' (no clinical evidence of disease, minimal abnormalities of uncertain
significance on radiological investigation) was achieved in a further seven patients and 'poor partial remission'
(a reduction in measurable disease >50%) in four, giving an overall response rate of 15/22 (68%). One
patient died within 48 h of arrival at the hospital; 16 of the 17 remaining patients in whom anything less than
CR was achieved subsequently received additional, alternative treatment (one chemotherapy, six mediastinal
radiotherapy, nine both treatment modalities) but in only 2/16 did this result in any further degree of response.
With a median follow-up of 51 years, 10/22 patients remain well without progression between 6 months and 14
years (5/6 in whom CR was eventually achieved and 5/11 in whom only partial remission was ever
documented). The seven patients in whom the initial treatment demonstrably failed have all died. These results
suggest that a proportion of patients with this rare subtype of high-grade B-cell lymphoma may be cured by
chemotherapy alone and that the presence of a residual mediastinal mass after treatment does not necessarily
imply treatment failure. However, patients in whom the initial chemotherapy fails have a very grave
prognosis.
In 1981, Miller et al. described the association of superior
vena caval obstruction with a specific subtype of non-
Hodgkin's lymphoma, characterised histologically by diffuse
large-cell proliferation with sclerosis. Subsequent reports
have suggested that this is a discrete clinical and pathological
entity (Trump et al., 1982; Yousem et al., 1985; Menestrina
et al., 1986; Perron et al., 1986; Scarpa et al., 1987; Jacobson
et al., 1988; Lamarre et al., 1989; Todeschini et al., 1990;
Al-Sharabati et al., 1991), although this concept has also
been questioned (Lister, 1991). The disease typically occurs in
younger adults and is characterised by the presence of a
mediastinal mass. Extranodal sites may be involved, and
some series (but not all) have described a propensity for
spread to unusual sites such as the kidney (Menestrina et al.,
1986; Perron et al., 1986; Todeschini et al., 1990).
Immunophenotypic and Southern blot analysis have
confirmed the tumour to be of B-cell origin (Yousem et al.,
1985; Mesentrina et al., 1986; Scarpa et al., 1987, 1991;
Lamarre et al., 1989). In some instances mediastinal large-cell
lymphoma with sclerosis (MLCLS) has been found to arise
in the thymus (Addis & Isaacson, 1986), and an origin from
native thymic medullary B-lymphocytes has therefore been
proposed (Isaacson et al., 1987). Molecular studies have dem-
onstrated alterations of the c-myc oncogene (Scarpa et al.,
1991).
This retrospective analysis describes the clinical course of
22 consecutive patients identified as having MLCLS over a
14 year period at St Bartholomew's Hospital (SBH).
Patients and methods
Patients
Between March 1978 and January 1992, a total of 399 newly
diagnosed patients with high-grade lymphoma (Kiel
classification) were referred to the ICRF Department of
Medical Oncology. Twenty-one were identified as having the
histological features of MLCLS.
Nine patients had originally been classified as having
mediastinal high-grade B-cell lymphoma, and a further two
patients were identified at histological review for a report
about treatment for high-grade lymphoma at SBH. The
remainder were identified by reviewing the slides of all
patients with lymphoma known to have mediastinal or pul-
monary involvement at presentation, referred over a 20 year
period.
The clinical characteristics of the group with MLCLS are
shown in Table I.
Diagnosis
The diagnosis was based on material obtained at thoractomy
(12 patients), lymph node biopsy (seven patients), Tru-cut
needle biopsy of a mediastinal mass (two patients) and
biopsy of a chest wall mass (one patient). The histology
typically showed large pleomorphic blast cells with relatively
plentiful cytoplasm which was either weakly eosinophilic or
'water-clear' on haematoxylin and eosin preparations. In
Table I Clinical characteristics
Median age (range) (years)
Gender (M/F)
SVC obstruction at presentation
Stage
II
IIE
IV
'Bulky' disease
Extranodal sites
Chest wall
Lung parenchyma
Adrenal + pancreas
Bone marrow
30 (19-71)
10:12
11
6
7
9
14
(16 patients)
4
8
I
1
Liver 2
Pleural effusiona 5
Pericardial thickening ± effusionb 9
aCytological examination revealed lymphoma cells. bOne effusion
necessitated drainage; the remainder were detected on CT scans in
otherwise asymptomatic patients.
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Figure 1 Duration of remission and survival.
most cases, there was dense sclerosis, which often gave the
tumour a packeted appearance; necrosis was also frequently
seen. A reactive infiltrate of small T lymphocytes was usually
present; in some of the mediastinal biopsies, residual thymic
epithelial cells were found on stains for cytokeratins.
Immunophenotyping was performed on paraffin sections
alone in six cases and on frozen sections in the remainder.
All tumours had a B-cell phenotype (either CD20 or CD22
positive). Only two tumours expressed C3d receptors (CD21)
and two tumours were weakly positive for the common acute
lymphoblastic leukaemia antigen (CD10). None of the
tumours expressed the CD5 antigen. A notable feature was
lack of stainable immunoglobulin light or heavy chains in
most cases. One patient was originally considered to have
Hodgkin's disease and received treatment on that basis.
When this was unsuccessful, review of the histology resulted
in the diagnosis and subsequent treatment being changed.
Table II Response to treatment
Initial and Rx atfurther
Patient no. subsequent Rx Outcome Rx at recurrence Outcome recurrence Outcome Now
2
3
4
5
6
MACOP
VAPEC-B
VAPEC B
VAPEC B
MACOP
RTH
MACOP
RTH
7 VAPEC B
8 VAPEC B
RTH
9 VAPEC-B
MACOP
10 MACOP
RTH
I1 MACOP
RTH
12 MACOP
VPl6+ARA-C
RTH
HD melphalan
+ABMT
13 CHOP
RTH
CHOP
14 MACOP
RTH
15 VAPEC B
RTH
16 MACOP
VP16 +ara-C
RTH
17 VAPEC-B
VP16+ara-C
RTH
18 MVPP
CHOP
R/TH
19 VAPEC-B (ps)
Palliative RTH
20 MACOP
VP16 +ara-c
HD MTX
RTH
21 MACOP
VAPEC-B (ps)
VAPEC B-*
MACOP
CR
CR
CR
CR
GPR
CR
GPR
CR
GPR
GPR
No change
GPR
No change
GPR
Progression
GPR
No change
Rx failed
Rx failed
GPR
No change
PPR
No change
No change
PPR
No change
PPR
No change
PPR
No change
No change
Rx failed
PPR
No change
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
Rx failed
MACOP Rx failed
RTH Rx failed
VP16+
ara-C
VP16+
ara-C
GPR
No change
RTH - PPR - CY+
TBI+ABMT
CAMPATH Rx failed
HD MTX Rx failed
MACOP Rx failed
HD Ara-C PPR
22 VAPEC B Inevaluable for response, died within 72 h
Key: RTH, radiotherapy; Rec, recurrence; WWP, well without progression; Rx, treatment; H/D, high dose. MACOP, adriamycin,
cyclophosphamide, vincristine and prednisolone+mid-cycle methotrexate (ref); VAPEC-B, a 12 week sequential regimen comprising adriamycin,
cyclophosphamide, vincristine and prednisolone +etoposide and bleomycin (ref); VAPEC-B ps, pilot study for the aboveregimen, bleomycin being
given by i.v. infusion over 24 h; VP16, etoposide; ara-C, cytosine arabinoside.
Entries in bold indicate maximum response achieved for each patient.
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and diedMEDIASTINAL LARGE-CELL LYMPHOMA WITH SCLEROSIS (MLCLS) 603
One patient developed MLCLS 11 years after receiving chemo-
therapy for documented stage IIB Hodgkin's disease.
Definitions
Clinical stage was defined on the basis of physical examina-
tion, full blood count, liver function tests, bone marrow
aspirate and trephine biopsy, chest radiograph and computed
tomographic (CT) scans of the chest and abdomen. 'Bulky'
disease was defined as a mediastinal mass measuring > 1/3 of
the internal thoracic diameter at D5/6.
Response was defined as follows:
Complete remission (CR): disappearance of all detectable
signs of disease.
Good partial remission (GPR): no clinical evidence of
disease but minimal residual abnormalities of uncertain
significance persisting on radiological investigation.
Poor partial remission (PPR): a reduction in measurable
disease of at least 50%.
Any lesser degree of response was deemed 'treatment
failure'.
Duration of remission and overall survival were calculated
according to the Kaplan-Meier method (Kaplan & Meier,
1973).
Treatment
Details of treatment are shown in Table II. The initial treat-
ment reflects the protocols for high-grade lymphoma in use
at the time (Whelan et al., 1992; Dhaliwal et al., 1993;
Radford et al., 1993). When this did not result in complete
remission being achieved (because of lack of response or an
incomplete response), alternative treatment (radiotherapy or
chemotherapy) was given in the hope of eventually achieving
CR. Thus, in Table II 'initial and subsequent treatment'
refers to the treatment or consecutive treatments given in an
attempt to achieve the maximum response. The four most
recently treated patients have electively received radiotherapy
(4,000cGy) to the mediastinum on completion of chemo-
therapy, following reports in the literature which suggested
improved survival with combined modality therapy (Jacob-
son et al., 1988; Todeschini et al., 1990; Al-Sharabati et al.,
1991).
Results
Response to therapy
The response to each phase of treatment and the maximum
response achieved are shown in detail in Table II. Complete
remission was achieved with the initial chemotherapy in only
4/22 patients, GPR in seven and PPR in four, giving an
overall response rate of 15/22 (68%). Seven patients showed
no evidence of response, one being moribund on arrival at
hospital; despite treatment being commenced, she died within
48 h.
Sixteen of the 17 patients in whom anything less than CR
was achieved subsequently received additional, alternative
therapy (one chemotherapy, six mediastinal radiotherapy,
nine both treatment modalities, Table II). However, in only
two did this result in a further documented radiological
response, i.e. GPR becoming CR. In two of the seven
patients in whom the initial treatment demonstrably failed,
the use of mediastinal radiotherapy or etoposide + high-dose
cytosine arabinoside (Whelan et al., 1992) resulted in GPR
and PPR being achieved eventually, but in both patients the
response was short-lived and both subsequently died. Thus, if
maximal rather than initial response is considered, the overall
response rate becomes 17/22 (77%) (six CR, six GPR, five
PPR). There were no treatment-related deaths.
Duration ofremission (Figure 1)
With a median follow-up of 51 years, 11/22 patients (5/6 CR,
3/6 GPR, 3/5 PPR) remain well without progression between
6 months and 14 years.
Site ofrecurrence
In all patients who developed recurrent disease, the pre-
dominant site was again the mediastinum.
Survival (Figure 1)
Twelve of the 22 patients remain alive, one having developed
progressive disease despite additional radiotherapy and hav-
ing subsequently received further, alternative chemotherapy.
Ten of the 13 patients presenting with stage II/IIE disease are
alive, compared with only two of the nine who had stage IV
disease at presentation.
Discussion
These results illustrate the experience of a single centre in the
management of a rare subtype of high-grade B-cell lym-
phoma. The patients were not uniformly treated, reflecting
developments in treatment approach. Although the number
of patients is small, the results clearly demonstrate that a
proportion of patients in whom this diagnosis is made are
potentially curable with chemotherapy alone. However, in
the majority, complete remission was not achieved with the
original treatment; whether it would have been had more
intensive initial therapy been used is debatable.
It has been suggested that therapy such as MACOP-B
(Klimo & Connors, 1985) improves both remission rate and
long-term outcome in patients with this diagnosis (Jacobson
et al., 1988; Todeschini et al., 1990; Bertini et al., 1991); it
has also been reported that radiotherapy, given as consolida-
tion of first remission, is advantageous (Jacobson et al., 1988;
Todeschini et al., 1990; Al-Sharabati., 1991). While the latter
contention cannot be proved in this series, half of the
patients who remain well without progression did in fact
receive radiotherapy at some point (Table II). In two patients
in whom GPR was achieved with the original chemotherapy,
radiotherapy did result in a further degree of response, at
least by radiological criteria (gallium scans were not per-
formed). On the other hand, in four patients, radiotherapy
did not result in any further radiological response.
In patients with lymphoma, it is well established that a
residual mediastinal shadow following chemotherapy may
not necessarily represent active disease. This observation has
most frequently been made in patients with Hodgkin's
disease (Jochelson et al., 1985; Chen et al., 1987; Radford et
al., 1988) but is also true for patients with high-grade non-
Hodgkin's lymphoma (Dhaliwal et al., 1993). In this series,
the presence of a residual mediastinal abnormality after treat-
ment certainly did not necessarily imply treatment failure,
provided at least a partial (> 50%) response had been
achieved. This is in contrast to the situation in patients in
whom the initial therapy demonstrably failed, in whom the
prognosis was extremely grave. In the latter group, tenuous
responses to one or other chemotherapy regimen were some-
times seen, only to be rapidly overtaken by relentless progres-
sion of, almost invariably, intrathoracic rather than
disseminated disease. The use of myeloablative therapy with
autologous bone marrow transplantation might arguably
have helped such patients, but on the two occasions in which
it was used recurrent lymphoma supervened within months.
Thus, although this is a tumour with a recognisable histo-
logical subtype and a typical clinical presentation, the situa-
tion for patients with MLCLS overall is no different from
that of patients with other types of high-grade B-cell lym-
phoma. The difference lies in the distribution of disease at
presentation, recurrence and progression when, almost
invariably, the predominant site remains the mediastinum.
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